Table 2 Annual and cumulative estimated HCV treatment uptake in Norway and Sweden among OAT patients 2014–2017
2014 | 2015 | 2016 | 2017 | |||||
|---|---|---|---|---|---|---|---|---|
Country | Norway | Sweden | Norway | Sweden | Norway | Sweden | Norway | Sweden |
HCV treatment n (overall) | 148 | 54 | 178 | 105 | 216 | 124 | 378 | 124 |
Study population n, | 6057 | 2663 | 6005 | 2640 | 5537 | 2683 | 5545 | 2739 |
HCV treatment % (95% CI) | 2.4 (2.1–2.8) | 2.0 (1.5–2.6) | 3.0 (2.5–3.4) | 4.0 (3.2–4.7) | 3.9 (3.4–4.4) | 4.6 (3.8–5.4) | 6.8 (6.2–7.5) | 4.5 (3.8–5.3) |
Expected proportion of OAT patients who are not PWID, na | 303 | 133 | 300 | 132 | 276 | 134 | 277 | 137 |
Expected Anti-HCV, weighted by PWID status, nb | 4651 | 2075 | 4612 | 2057 | 4252 | 2091 | 4258 | 2135 |
Expected chronic HCV after spontaneous clearance, n (UI)c | 3442 (3303–3628) | 1536 (1474–1619) | 3413 (3274–3597) | 1523 (1461–1605) | 3147 (3019–3317) | 1547 (1485–1631) | 3151 (3023–3321) | 1580 (1516–1665) |
Expected chronic HCV after treatment, n (UI) | 3294 (3155–3480) | 1482 (1420–1565) | 3235 (3096–3419) | 1418 (1356–1500) | 2931 (2803–3101) | 1423 (1361–1507) | 2773 (2645–2943) | 1456 (1392–1541) |
Expected chronic HCV after spontaneous clerance and treatment, % (UI) | 54.4 (52.1–57.5) | 55.6 (53.3–58.8) | 53.9 (51.6–56.9) | 53.7 (51.4–56.8) | 52.9 (50.6–56.0) | 53.1 (50.7–56.2) | 50.0 (47.7–53.1) | 53.1 (50.8–56.3) |
Estimated HCV treatment uptake % (UI) | 4.5 (4.3–4.7) | 3.6 (3.5–3.8) | 5.5 (5.2–5.7) | 7.4 (7.0–7.7) | 7.4 (7.0–7.7) | 8.7 (8.2–9.1) | 13.6 (12.8–14.3) | 8.5 (8.0–8.9) |
Estimated HCV cumulative treatment uptake % (UI) | 4.5 (4.3–4.7) | 3.6 (3.5–3.8) | 10.0 (9.5–10.4) | 11.1 (10.5–11.5) | 17.4 (16.4–18.1) | 19.8 (18.7–20.7) | 31.0 (29.3–32.4) | 28.3 (26.7–29.6) |